A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 7 doses of subcutaneous lirentelimab.

Key facts

Study ID

NCT05155085

Run by

Allakos Inc.

People needed

131

Starts

2022-06-27

Expected to finish

2024-04-17

Last updated by the study team

2024-10-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Allakos Investigational Site 218-074 — Cullman, Alabama, United States
• Allakos Investigational Site 218-025 — Gilbert, Arizona, United States
• Allakos Investigational Site 218-041 — Scottsdale, Arizona, United States
• Allakos Investigational Site 218-072 — Canoga Park, California, United States
• Allakos Investigational Site 218-056 — Los Angeles, California, United States
• Allakos Investigational Site 218-073 — San Diego, California, United States
• Allakos Investigational Site 218-051 — San Francisco, California, United States
• Allakos Investigational Site 218-013 — Santa Monica, California, United States
• Allakos Investigational Site 218-033 — Santa Monica, California, United States
• Allakos Investigational Site 218-071 — Colorado Springs, Colorado, United States
• Allakos Investigational Site 218-045 — Washington D.C., District of Columbia, United States
• Allakos Investigational Site 218-018 — Doral, Florida, United States
• Allakos Investigational Site 218-046 — Greenacres City, Florida, United States
• Allakos Investigational Site 218-049 — Jacksonville, Florida, United States
• Allakos Investigational Site 218-008 — Miami, Florida, United States
• Allakos Investigational Site 218-048 — Sarasota, Florida, United States
• Allakos Investigational Site 218-020 — Tampa, Florida, United States
• Allakos Investigational Site 218-007 — Tampa, Florida, United States
• Allakos Investigational Site 218-068 — Lexington, Kentucky, United States
• Allakos Investigational Site 218-055 — Crowley, Louisiana, United States
• Allakos Investigational Site 218-012 — Towson, Maryland, United States
• Allakos Investigational Site 218-069 — White Marsh, Maryland, United States
• Allakos Investigational Site 218-066 — Boston, Massachusetts, United States
• Allakos Investigational Site 218-058 — Dilworth, Minnesota, United States
• Allakos Investigational Site 218-034 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.